Stay updated on ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial page.

Latest updates to the ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial page
- ChecktodayChange DetectedThe ClinicalTrials.gov site footer now displays revision v3.8.1 instead of v3.8.0. The study record content remains unchanged.SummaryDifference0.1%

- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe site footer revision number changed from v3.7.2 to v3.8.0.SummaryDifference0.1%

- Check28 days agoChange DetectedA site-wide NIH notice says federal agencies are transitioning from “Artificial Intelligence” to “Super Intelligence,” and the displayed site revision advances from v3.7.1 to v3.7.2.SummaryDifference0.7%

- Check42 days agoChange DetectedThe ClinicalTrials.gov footer revision label changed from v3.7.0 to v3.7.1.SummaryDifference0.1%

- Check56 days agoChange DetectedA new Study Status section was added to the record history on 2026-09-22, and a new version entry dated 2026-09-21 (version 14) was created to reflect updated status. Additionally, the prior entry dated 2026-04-13 was removed from the history.SummaryDifference0.4%

- Check63 days agoChange DetectedThe record history now includes a new revision labeled v3.7.0. The previous revision v3.6.6 has been removed, indicating a version update to the page rather than changes to the study content.SummaryDifference0.1%

Stay in the know with updates to ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial page.